CHGCF:OTC-Chugai Pharmaceutical Co. Ltd (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 32.43

Change

0.00 (0.00)%

Market Cap

USD 56.24B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZNCF AstraZeneca PLC

N/A

USD 240.18B
NVSEF Novartis AG

N/A

USD 208.10B
RHHBY Roche Holding Ltd ADR

N/A

USD 202.85B
RHHBF Roche Holding AG

N/A

USD 202.85B
RHHVF Roche Holding AG Participation

N/A

USD 202.50B
SNYNF Sanofi

N/A

USD 127.07B
GLAXF GSK plc

N/A

USD 92.19B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 66.43B
DSKYF Daiichi Sankyo Company Limited

N/A

USD 66.43B
CHGCY Chugai Pharmaceutical Co Ltd A..

N/A

USD 52.77B

ETFs Containing CHGCF

1638:TSE 6.85 % 0.00 %

N/A

N/A
JPMV:PA 2.60 % 0.00 %

N/A

N/A
OSXJ:XETRA 2.60 % 0.00 %

N/A

N/A
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.35% 48% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.35% 47% F 31% F
Trailing 12 Months  
Capital Gain 24.73% 94% A 80% B-
Dividend Return 2.40% 48% F 33% F
Total Return 27.13% 94% A 80% B-
Trailing 5 Years  
Capital Gain 54.43% 88% B+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.43% 84% B 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 18.40% 97% N/A 65% D
Dividend Return 19.76% 82% B 63% D
Total Return 1.35% 30% F 35% F
Risk Return Profile  
Volatility (Standard Deviation) 61.74% 15% F 43% F
Risk Adjusted Return 32.00% 68% D+ 68% D+
Market Capitalization 56.24B 75% C 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.